EasySep™ Release Human CD45 Positive Selection Kit

Immunomagnetic positive selection of human CD45+ leukocytes, including TILs, using particle release technology

EasySep™ Release Human CD45 Positive Selection Kit

Immunomagnetic positive selection of human CD45+ leukocytes, including TILs, using particle release technology

From: 779 USD
Catalog #
(Select a product)
Immunomagnetic positive selection of human CD45+ leukocytes, including TILs, using particle release technology
Add to Wish List

Product Advantages


  • Highly purified CD45+ cells isolated in less than 45 minutes

  • No-wash removal of EasySep™ Releasable RapidSpheres™

What's Included

  • EasySep™ Release Human CD45 Positive Selection Kit (Catalog #100-0105)
    • EasySep™ Release Human CD45 Positive Selection Cocktail, 0.5 mL
    • EasySep™ Releasable RapidSpheres™, 1 mL
    • EasySep™ Release Buffer (Concentrate), 6 x 1 mL
  • RoboSep™ Release Human CD45 Positive Selection Kit (Catalog #100-0108)
    • EasySep™ Release Human CD45 Positive Selection Cocktail, 0.5 mL
    • EasySep™ Releasable RapidSpheres™, 1 mL
    • EasySep™ Release Buffer (Concentrate), 6 x 1 mL
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125)
    • EasySep™ EasyTube™-14 (Catalog #20128)
  • EasySep™ Release Human CD45 Positive Selection Kit for Humanized Mice (Catalog #100-0107)
    • EasySep™ Release Human CD45 Positive Selection Cocktail, 0.5 mL
    • EasySep™ Releasable RapidSpheres™, 1 mL
    • EasySep™ Release Buffer (Concentrate), 6 x 1 mL
    • EasySep™ Mouse FcR Blocker, 0.5 mL
  • RoboSep™ Release Human CD45 Positive Selection Kit for Humanized Mice (Catalog #100-0109)
    • EasySep™ Release Human CD45 Positive Selection Cocktail, 0.5 mL
    • EasySep™ Releasable RapidSpheres™, 1 mL
    • EasySep™ Release Buffer (Concentrate), 6 x 1 mL
    • EasySep™ Mouse FcR Blocker, 0.5 mL
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125) x 2
    • EasySep™ EasyTube™-14 (Catalog #20128) x 2
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

Overview

Easily isolate highly purified and magnetic particle-free human CD45+ leukocytes from single-cell suspensions of primary human tissues and tumors (Catalog #100-0105), or tissues and tumor xenografts from humanized mice (Catalog #100-0107) samples, by immunomagnetic positive selection, with the EasySep™ Release Human CD45 Positive Selection Kit. Widely used in published research for more than 20 years, EasySep™ combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.

In this EasySep™ positive selection procedure, desired cells are first labeled with antibody complexes recognizing CD45 and magnetic particles called EasySep™ Releasable RapidSpheres™. Unlike traditional magnetic particles, which stay bound to the target cells, these RapidSpheres™ have a releasable feature. After separation using an EasySep™ magnet, bound magnetic particles are removed from the EasySep™-isolated CD45+ cells using a release agent, and unwanted cells are targeted for depletion. The final isolated fraction contains highly purified CD45+ cells that are immediately ready for downstream applications such as flow cytometry, culture, or DNA/RNA extraction. Following cell isolation with this EasySep™ kit, antibody complexes remain bound to the cell surface and may interact with Brilliant Violet™ antibody conjugates, polyethylene glycol-modified proteins, or other chemically related ligands.

Learn more about how immunomagnetic EasySep™ technology works or how to fully automate immunomagnetic cell isolation with RoboSep™. Explore additional products optimized for your workflow, including those for culture media, supplements, antibodies, and more.


Magnet Compatibility
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• EasyPlate™ EasySep™ Magnet (Catalog #18102)
• RoboSep™-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
Leukocytes
Species
Human, Mouse
Sample Source
Other, Tumor
Selection Method
Positive
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Cancer, Immunology

Data Figures

Using the EasySep™ Release Human CD45 Positive Selection Kit, the CD45+ TIL purities of the start and final isolated fractions are 5.5% and 96.0%, respectively.

Figure 1. EasySep™ Release Human CD45 Positive Selection Kit

Starting with a single-cell suspension of a human breast cancer tumor xenograft (MDA-MB-231) sample from an NRG-3GS humanized mouse, the CD45+ TIL purities of the start and final isolated fractions are 5.5% and 96.0%, respectively.
NOTE: Cell debris and dead cells were excluded from the analysis based on DRAQ5™ and DAPI fluorescence.

Using PBMCs as a startnig sample, this t-SNE plot shows that EasySep™-isolated CD45+ cells are representative of the starting leukocyte population.

Figure 2. EasySep™-Isolated CD45+ Cells are Representative of the Starting Leukocyte Population

Mass cytometry data comparing the composition of immune subsets in PBMCs and EasySep™-isolated cells from the same donor. Starting with whole blood, PBMCs were prepared by density gradient centrifugation using Lymphoprep™. To compare immune subset composition pre- and post-EasySep™ isolation, a fraction of the PBMCs was further isolated using EasySep™ Release Human CD45 Positive Selection Kit and the pre- and post-isolated fractions were assessed by mass cytometry (CyTOF®). t-SNE plots of cells stained with 19 markers and analyzed by CyTOF® are shown (n = 1).

PBMCs pre- and post-EasySep™ isolation were incubated in peptide pools (CEF, CPI, or PHA) and a robust population of IFN-gamma-producing cells in these respective samples are visible on ELISpot plates, showing that EasySep™-isolated CD45+ cells produce IFN-gamma in response to antigen and mitogen stimulation.

Figure 3. EasySep™-Isolated CD45+ Cells Produce IFN-gamma in Response to Antigen and Mitogen Stimulation

PBMCs pre- and post-EasySep™ isolation were incubated for 24 hours in the presence of peptide pools (CEF for antigen-specific CD8+ T cell response and CPI for antigen-specific CD4+ T cell response) or mitogen (phytohemagglutinin [PHA]). Following incubation, ELISpot plates were processed and IFN-gamma-producing cells were counted using an AID ELISpot reader. Representative images of ELISpot assays are shown (n = 3).

CD45+ cells isolated from spleens, lungs, bone marrow, MDA MB231 tumors, and SKOV3 tumors using EasySep™ are highly purified.

Figure 4. CD45+ Cells Isolated by EasySep™ from Various Tissues Are Highly Purified

A humanized mouse tumor model was generated by engraftment of human CD34+ hematopoietic stem and progenitor cells into NRG-3GS mice followed by xenotransplantation with human cancer cell lines, MDA-MB-231 (breast cancer) or SKOV-3 (ovarian carcinoma). Starting with a single-cell suspension of spleens, lungs, bone marrow, or tumors, human CD45+ leukocytes were isolated using EasySep™ Release Human CD45 Positive Selection Kit. The starting frequencies and isolated purities of human CD45+ cells of individual experiments and averages are shown.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
100-0108
Lot #
1000170438 or lower
Language
English
Catalog #
100-0108
Lot #
1000170439 or higher
Language
English
Catalog #
100-0109
Lot #
1000170439 or higher
Language
English
Catalog #
100-0109
Lot #
1000170438 or lower
Language
English
Catalog #
100-0105
Lot #
1000170439 or higher
Language
English
Catalog #
100-0105
Lot #
1000170438 or lower
Language
English
Catalog #
100-0107
Lot #
1000170438 or lower
Language
English
Catalog #
100-0107
Lot #
1000170439 or higher
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0108
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0108
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0108
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
100-0108
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 6
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0105
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0105
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0105
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0107
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0107
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0107
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
100-0107
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Catalog #
100-0107
Lot #
All
Language
English

Resources and Publications

Publications (1)

Dynamic alterations in PD-1/PD-L1 expression level and immune cell profiles based on radiation response status in mouse tumor model. Y. N. Yoon et al. Frontiers in oncology 2022

Abstract

INTRODUCTION Based on the immunologic effects of anti-cancer treatment and their therapeutic implications, we evaluated radiotherapy (RT)-induced dynamic alterations in programmed death-1 (PD-1)/PD ligand-1 (PD-L1) expression profiles. METHODS Local RT with 2 Gy ?— 5 or 7.5 Gy ?— 1 was administered to the CT26 mouse model. Thereafter, tumors were resected and evaluated at the following predefined timepoints according to radiation response status: baseline, early (immediately after RT), middle (beginning of tumor shrinkage), late (stable status with RT effect), and progression (tumor regrowth). PD-1/PD-L1 activity and related immune cell profiles were quantitatively assessed. RESULTS RT upregulated PD-L1 expression in tumor cells from the middle to late phase; however, the levels subsequently decreased to levels comparable to baseline in the progression phase. RT with 2 Gy ?— 5 induced a higher frequency of PD-L1+ myeloid-derived suppressor cells, with a lesser degree of tumor regression, compared to 7.5 Gy. The proportion of PD-1+ and interferon (IFN)-$\gamma$+CD8$\alpha$ T cells continued to increase. The frequency of splenic PD-1+CD8+ T cells was markedly elevated, and was sustained longer with 2 Gy ?— 5. Based on the transcriptomic data, RT stimulated the transcription of immune-related genes, leading to sequentially altered patterns. DISCUSSION The dynamic alterations in PD-1/PD-L1 expression level were observed according to the time phases of tumor regression. This study suggests the influence of tumor cell killing and radiation dosing strategy on the tumor immune microenvironment.